- Alefacept
drugs.com monograph alefacept MedlinePlus a603011 pregnancy AU C pregnancy US B legal US Rx only routes ... data C 2306 H 3594 N 610 O 694 S 26 molecular weight 51801.1 g mol Alefacept is a genetic engineering ... drug market. Alefacept is used to control inflammation in moderate to severe psoriasis with plaque ... T cell lymphoma and T cell non Hodgkin lymphoma . Alefacept is a fusion protein it combines part ..., alefacept leads to clinical improvement of moderate to severe psoriasis by blunting these reactions.Combinations ... psoriasis. ref Scheinfeld N. Therapy resistant psoriasis treated with alefacept and subsequent narrow ... has so far rejected to approve alefacept. Indications Alefacept is indicated for the management of patients ... during the treatment phase with alefacept and does not seem to pose any additional risks. The drug ... completion of a second alefacept treatment were also seen. Often the remission medicine remission s were maintained for 7 to 12 months after end of treatment. Contraindications and precautions Alefacept ... malignancy Caution Patients at high risk to develop a systemic malignancy Known hypersensitivity to alefacept .... Pregnancy and lactation Alefacept has been assigned to Pregnancy Category B in the US and to C in Australia ... antibodies to alefacept About 3 of patients developed low titer antibodies with unknown importance ... are attributable to alefacept therapy, but it is recommended to discontinue therapy ... should not receive alefacept in order to avoid the risks of excessive immunosuppression. Studies ... J, Sweetser M, Ticho B title Alefacept in combination with ultraviolet B phototherapy for the treatment ... volume 5 issue 7 pages 623 8 year 2006 pmid 16865867 cite journal author Krell J title Use of alefacept ... cite journal author Parrish C, Sobera J, Robbins C, Cantrell W, Desmond R, Elewski B title Alefacept ... Immunosuppressants it Alefacept pl Alefacept ... more details
|
- ATC code L04
ATC codes lead L 04 Immunosuppressants anchor L04A L04A Immunosuppressants anchor L04AA L04AA Selective immunosuppressants L04AA02 Muromonab CD3 L04AA03 Antilymphocyte immunoglobulin horse L04AA04 Antithymocyte immunoglobulin rabbit L04AA06 Mycophenolic acid L04AA10 Sirolimus L04AA13 Leflunomide L04AA15 Alefacept L04AA18 Everolimus L04AA19 Gusperimus L04AA21 Efalizumab L04AA22 Abetimus L04AA23 Natalizumab L04AA24 Abatacept L04AA25 Eculizumab L04AA26 Belimumab L04AA27 Fingolimod L04AA28 Belatacept anchor L04AB L04AB Tumor necrosis factor alpha TNF inhibitors L04AB01 Etanercept L04AB02 Infliximab L04AB03 Afelimomab L04AB04 Adalimumab L04AB05 Certolizumab pegol L04AB06 Golimumab anchor L04AC L04AC Interleukin inhibitors L04AC01 Daclizumab L04AC02 Basiliximab L04AC03 Anakinra L04AC04 Rilonacept L04AC05 Ustekinumab L04AC06 Mepolizumab L04AC07 Tocilizumab L04AC08 Canakinumab L04AC09 Briakinumab L04AC10 Secukinumab anchor L04AD L04AD Calcineurin inhibitors L04AD01 Ciclosporin L04AD02 Tacrolimus L04AD03 Voclosporin anchor L04AX L04AX Other immunosuppressants L04AX01 Azathioprine L04AX02 Thalidomide L04AX03 Methotrexate L04AX04 Lenalidomide L04AX05 Pirfenidone References Reflist Immunosuppressants Category ATC codes L04 Category Immunosuppressants ca Codi ATC L04 cs ATC k d L04 es Anexo C digo ATC L04 ko ATC L04 hu ATC L04 Immunszuppressz v szerek pl ATC L04 ro Cod ATC L04 sv ATC kod L04 Immunsuppressiva medel th ATC L04 ... more details
|
- Astellas Pharma
rejection Protopic tacrolimus ointment Atopic dermatitis eczema Amevive alefacept Plaque psoriasis ... more details
|
- Hailey?Hailey disease
, cyclosporine and, most recently, intramuscular alefacept may control the disease but are ineffective ... more details
|
- Neonatal Fc receptor
to increase its halflife. They are Amevive alefacept , Arcalyst rilonacept , Enbrel etanercept , Nplate ... more details
|
- List of drugs: Al
List of drugs A Al ala alb Ala Cort Ala Quin Ala Scalp Ala Tet alacepril International Nonproprietary Name INN alacizumab pegol International Nonproprietary Name INN alafosfalin International Nonproprietary Name INN alagebrium chloride United States Adopted Name USAN Alamast alanine International Nonproprietary Name INN alanosine International Nonproprietary Name INN alaproclate International Nonproprietary Name INN alatrofloxacin International Nonproprietary Name INN Alavert alazanine triclofenate International Nonproprietary Name INN albaconazole United States Adopted Name USAN Albalon Albamycin albendazole oxide International Nonproprietary Name INN albendazole International Nonproprietary Name INN Albenza Albert Tiafen albifylline International Nonproprietary Name INN albiglutide United States Adopted Name USAN albinterferon alfa 2B United States Adopted Name USAN , International Nonproprietary Name INN albitiazolium bromide International Nonproprietary Name INN albuglutide International Nonproprietary Name INN Albuminar Albunex Albutein albuterol International Nonproprietary Name INN albutoin International Nonproprietary Name INN alc ale alcaftadine United States Adopted Name USAN , International Nonproprietary Name INN Alcaine Alcalak alclofenac International Nonproprietary Name INN alclometasone International Nonproprietary Name INN alcloxa International Nonproprietary Name INN alcohol , the type known as ethanol Alcomicin Alconefrinasal Solution alcuronium chloride International Nonproprietary Name INN Aldactazide Aldactone Imiquimod Aldara 3m , also known as imiquimod aldesleukin International Nonproprietary Name INN aldesulfone sodium International Nonproprietary Name INN aldioxa International Nonproprietary Name INN Aldoclor Aldomet Merck & Co. Merck , also known as methyldopa Aldoril aldosterone International Nonproprietary Name INN Aldurazyme alefacept United States Adopted Name USAN aleglitazar United States Adopted Name USAN , International Nonproprie ... more details
|
- Biogen Idec
partner Bayer Schering Pharma . In 2006, the company sold rights for Amevive alefacept , another ... more details
|
- Biologic medical product
TNF receptor antagonist antagonist alefacept Amevive chronic plaque psoriasis immunoglobin G1 fusion ... more details
|
- Psoriasis
Alefacept induced decreases in circulating blood lymphocyte counts correlate with clinical response ... T cells are efalizumab and alefacept . Efalizumab is a monoclonal antibody which blocks the molecules ... was voluntarily withdrawn from the US market in April, 2009 by the manufacturer. Alefacept ... more details
|
Encyclopedia
top
